7 February 2019

Exposure therapy is effective in about half of the patients with post-traumatic stress syndrome (PTSD). This percentage may possibly increase due to the targeted use of cortisol in the right patients. Benno Roozendaal received a TOP subsidy from ZonMw to investigate this. For this study he will collaborate with Erno Hermans, Robbert-Jan Verkes and Gert-Jan Hendriks.

Posttraumatic stress disorder (PTSD) is a serious psychiatric disorder, characterized by uncontrollable anxiety reactions. The disorder can be the result of drastic traumatic events earlier in life, such as sexual or physical abuse or war experiences. Exposure therapy is a therapy where patients recall the trauma, while in a safe environment. In this way an attempt is made to permanently reduce the anxiety of the patient.


Exposure therapy is one of the most common and effective treatments for PTSD. Nevertheless, it only works in about half of the patients. It’s unknown why it doesn’t work for others.

With the TOP grant, Benno Roozendaal and his colleagues will investigate whether the stress hormone cortisol can be used to predict the success of exposure therapy. Normally cortisol is released when someone ends up in a stressful situation. The hormone plays a role in the ability to respond well in the situation at hand.

Fear reduction

Roozendaal: "In some patients we see a weak cortisol response, especially in patients who have experienced traumatic experiences in early childhood. Apparently something is wrong with their stress response. We are going to investigate that now, first of all in rats. We examine whether a weakened cortisol response in these animals indeed leads to a weaker reduction of the anxiety reaction.”

“If so, it becomes interesting to investigate whether cortisol can cause anxiety reduction in patients with PTSD. And even more specifically: whether that has an effect especially in patients with such a disturbed, weaker cortisol response.”

Related news items

Three Vici grants for Radboudumc researchers

20 February 2020

Christian Beckmann, Sander Leeuwenburgh and Annette Schenck each receive a 1.5 million euro Vici research grant from NWO.

read more

Dutch Brain Foundation grant for EENnacoma

20 February 2020

Lavrijsen and Van Erp: ‘This grant will facilitate practice-based research, professionalization and further academization of EENnacoma, and links between different health care and research institutions all for the benefit of people with prolonged disorders of consciousness and their families.'

read more

RIHS Awards Ceremony five winners

19 February 2020

On 18 February the RIHS 'Koek & Zopie' event took place. In front of an audience of more than 125 colleagues, RIHS awardees accepted their awards for the best PhD thesis, the research product with the highest impact on society, the best peer-reviewed publication and the Supervisor of the year 2019.

read more

Preserved specific force in facioscapulohumeral muscular dystrophy

19 February 2020

DCMN researcher Saskia Lassche et al., theme Disorders of Movement, recently showed in Neurology that remaining muscle fibers in Facioscapulohumeral muscular dystrophy (FSHD) patients  have normal muscle strength, even in severely affected muscles.

read more

Researchers investigate how stem cells affect the immune system

18 February 2020

RIMLS researchers Irma Joosten and Renate van der Molen, participating in an European study into the treatment of brain damage in premature babies. Is it possible to limit or even partly repair the damage with stem cells? They focus primarily on the effect of those stem cells on the immune system.

read more

Lowlands Science call for projects

17 February 2020

Researchers pay attention! Lowlands is looking for research teams to participate in Lowlands Science 2020. It’s a great way to reach a large audience, do unique experiments with and on them, and to have a memorable experience with your colleagues.

read more